Document is current
Any future updates will be listed below
-
Authors
Wünnemann, Florian
Sicklinger, Florian https://orcid.org/0009-0004-6707-1695
Bestak, Kresimir https://orcid.org/0009-0009-8245-9846
Nimo, Jose
Thiemann, Tobias https://orcid.org/0009-0003-7284-2127
Amrute, Junedh M. https://orcid.org/0000-0002-6851-0168
Nordbeck, Mathias https://orcid.org/0009-0003-0392-6685
Hartmann, Niklas https://orcid.org/0009-0009-1799-7162
Ibarra-Arellano, Miguel A. https://orcid.org/0000-0001-8411-4854
Tanevski, Jovan https://orcid.org/0000-0001-7177-1003
Chazotte, Margot https://orcid.org/0009-0007-4901-5173
Heine, Clara https://orcid.org/0009-0001-3506-2119
Frey, Norbert
Lavine, Kory J. https://orcid.org/0000-0003-1948-9945
Coscia, Fabian https://orcid.org/0000-0002-2244-5081
Saez-Rodriguez, Julio https://orcid.org/0000-0002-8552-8976
Leuschner, Florian https://orcid.org/0000-0003-1157-474X
Schapiro, Denis https://orcid.org/0000-0002-9391-5722
- License Information
-
More Information
Article History
Received: 24 April 2024
Accepted: 20 August 2025
First Online: 3 October 2025
Competing interests
: D.S. reports funding from GlaxoSmithKline and receiving fees/honoraria from ariadne.ai, GlaxoSmithKline, Immunai, Noetik, Alpenglow and Lunaphore. K.B. reports fees from Lunaphore. J.S.R. reports funding from GlaxoSmithKline, Pfizer and Sanofi and fees/honoraria from Travere Therapeutics, Stadapharm, Astex, Owkin, Pfizer and Grunenthal. F.W. is an employee of Seqera. The other authors declare no competing interests.
